Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Quantitation of DNA Methylation by Quantitative Multiplex Methylation-Specific PCR (QM-MSP) Assay.

Fackler MJ, Sukumar S.

Methods Mol Biol. 2018;1708:473-496. doi: 10.1007/978-1-4939-7481-8_24.

PMID:
29224159
2.

Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.

Connolly RM, Fackler MJ, Zhang Z, Zhou XC, Goetz MP, Boughey JC, Walsh B, Carpenter JT, Storniolo AM, Watkins SP, Gabrielson EW, Stearns V, Sukumar S.

Breast Cancer Res Treat. 2018 Jan;167(1):107-116. doi: 10.1007/s10549-017-4503-2. Epub 2017 Sep 16.

PMID:
28918548
3.

Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk.

Stearns V, Fackler MJ, Hafeez S, Bujanda ZL, Chatterton RT, Jacobs LK, Khouri NF, Ivancic D, Kenney K, Shehata C, Jeter SC, Wolfman JA, Zalles CM, Huang P, Khan SA, Sukumar S.

Cancer Prev Res (Phila). 2016 Aug;9(8):673-682. doi: 10.1158/1940-6207.CAPR-15-0377. Epub 2016 Jun 3.

4.

Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.

Wu X, Zahari MS, Ma B, Liu R, Renuse S, Sahasrabuddhe NA, Chen L, Chaerkady R, Kim MS, Zhong J, Jelinek C, Barbhuiya MA, Leal-Rojas P, Yang Y, Kashyap MK, Marimuthu A, Ling M, Fackler MJ, Merino V, Zhang Z, Zahnow CA, Gabrielson E, Stearns V, Roa JC, Sukumar S, Gill PS, Pandey A.

Oncotarget. 2015 Oct 6;6(30):29143-60. doi: 10.18632/oncotarget.5020.

5.

Erratum to: Modeling precision treatment of breast cancer.

Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW.

Genome Biol. 2015 May 12;16:95. doi: 10.1186/s13059-015-0658-5.

6.

Do breast cancer cell lines provide a relevant model of the patient tumor methylome?

Cope LM, Fackler MJ, Lopez-Bujanda Z, Wolff AC, Visvanathan K, Gray JW, Sukumar S, Umbricht CB.

PLoS One. 2014 Aug 26;9(8):e105545. doi: 10.1371/journal.pone.0105545. eCollection 2014.

7.

Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.

Fackler MJ, Lopez Bujanda Z, Umbricht C, Teo WW, Cho S, Zhang Z, Visvanathan K, Jeter S, Argani P, Wang C, Lyman JP, de Brot M, Ingle JN, Boughey J, McGuire K, King TA, Carey LA, Cope L, Wolff AC, Sukumar S.

Cancer Res. 2014 Apr 15;74(8):2160-70. doi: 10.1158/0008-5472.CAN-13-3392. Erratum in: Cancer Res. 2014 Jun 1;74(11):3196.

8.

Modeling precision treatment of breast cancer.

Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, van't Veer LJ, Spellman PT, Gray JW.

Genome Biol. 2013;14(10):R110. Erratum in: Genome Biol. 2015;16:95.

9.

Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics.

Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, Kaspi A, Hu R, Robens J, Nikolskaya T, Haakensen VD, Schnitt SJ, Argani P, Ethington G, Panos L, Grant M, Clark J, Herlihy W, Lin SJ, Chew G, Thompson EW, Greene-Colozzi A, Richardson AL, Rosson GD, Pike M, Garber JE, Nikolsky Y, Blum JL, Au A, Hwang ES, Tamimi RM, Michor F, Haviv I, Liu XS, Sukumar S, Polyak K.

Cell Stem Cell. 2013 Jul 3;13(1):117-30. doi: 10.1016/j.stem.2013.05.004. Epub 2013 Jun 13.

10.

Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.

Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, Teo WW, Zhang Z, Huang P, Visvananthan K, Marks J, Ethier S, Gray JW, Wolff AC, Cope LM, Sukumar S.

Cancer Res. 2011 Oct 1;71(19):6195-207. doi: 10.1158/0008-5472.CAN-11-1630. Epub 2011 Aug 8.

11.

Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort.

Swift-Scanlan T, Vang R, Blackford A, Fackler MJ, Sukumar S.

Cancer Biol Ther. 2011 May 15;11(10):853-65. Epub 2011 May 15.

12.

Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer.

Lo PK, Lee JS, Liang X, Han L, Mori T, Fackler MJ, Sadik H, Argani P, Pandita TK, Sukumar S.

Cancer Res. 2010 Jul 15;70(14):6047-58. doi: 10.1158/0008-5472.CAN-10-1576. Epub 2010 Jun 29.

13.

Basal-like breast cancer displays distinct patterns of promoter methylation.

Lee JS, Fackler MJ, Lee JH, Choi C, Park MH, Yoon JH, Zhang Z, Sukumar S.

Cancer Biol Ther. 2010 Jun 15;9(12):1017-24. Epub 2010 Jun 18.

14.

Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens.

Kim JH, Choi YD, Lee JS, Lee JH, Nam JH, Choi C, Kweon SS, Fackler MJ, Sukumar S.

Virchows Arch. 2010 Jul;457(1):35-42. doi: 10.1007/s00428-010-0936-2. Epub 2010 May 23.

PMID:
20496080
15.

Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women.

Kim JH, Shin MH, Kweon SS, Park MH, Yoon JH, Lee JS, Choi C, Fackler MJ, Sukumar S.

Gynecol Oncol. 2010 Aug 1;118(2):176-81. doi: 10.1016/j.ygyno.2010.04.016. Epub 2010 May 13.

PMID:
20466412
16.

Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge.

Fackler MJ, Rivers A, Teo WW, Mangat A, Taylor E, Zhang Z, Goodman S, Argani P, Nayar R, Susnik B, Sukumar S, Khan SA.

Clin Cancer Res. 2009 Jun 1;15(11):3802-11. doi: 10.1158/1078-0432.CCR-08-1981. Epub 2009 May 26.

17.

Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis.

Lee JS, Fackler MJ, Teo WW, Lee JH, Choi C, Park MH, Yoon JH, Zhang Z, Argani P, Sukumar S.

Cancer Biol Ther. 2008 Sep;7(9):1398-406. Epub 2008 Sep 4.

PMID:
18769130
18.

Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer.

Suijkerbuijk KP, Fackler MJ, Sukumar S, van Gils CH, van Laar T, van der Wall E, Vooijs M, van Diest PJ.

Ann Oncol. 2008 Nov;19(11):1870-4. doi: 10.1093/annonc/mdn409. Epub 2008 Jul 22.

19.

Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases.

Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S, Argani P.

Clin Cancer Res. 2008 Apr 1;14(7):1938-46. doi: 10.1158/1078-0432.CCR-07-4082.

20.
21.

Id1 expression is transcriptionally regulated in radial growth phase melanomas.

Ryu B, Kim DS, DeLuca AM, Healey MA, Dunlap S, Fackler MJ, Herman J, Alani RM.

Int J Cancer. 2007 Oct 15;121(8):1705-9.

22.

Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls.

Locke I, Kote-Jarai Z, Fackler MJ, Bancroft E, Osin P, Nerurkar A, Izatt L, Pichert G, Gui GP, Eeles RA.

Breast Cancer Res. 2007;9(1):R20.

23.

Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid.

Fackler MJ, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlan T, Lange J, Nayar R, Davidson NE, Khan SA, Sukumar S.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3306-10.

24.

Two-color quantitative multiplex methylation-specific PCR.

Swift-Scanlan T, Blackford A, Argani P, Sukumar S, Fackler MJ.

Biotechniques. 2006 Feb;40(2):210-9.

25.

Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer.

Lo PK, Mehrotra J, D'Costa A, Fackler MJ, Garrett-Mayer E, Argani P, Sukumar S.

Cancer Biol Ther. 2006 Mar;5(3):281-6. Epub 2006 Mar 6.

PMID:
16410723
26.

Hypermethylation in histologically distinct classes of breast cancer.

Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, Herman JG, Gabrielson E.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5998-6005.

27.

Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer.

Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, Garrett E, Argani P, Sukumar S.

Cancer Res. 2004 Jul 1;64(13):4442-52.

28.

Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung.

Mehrotra J, Vali M, McVeigh M, Kominsky SL, Fackler MJ, Lahti-Domenici J, Polyak K, Sacchi N, Garrett-Mayer E, Argani P, Sukumar S.

Clin Cancer Res. 2004 May 1;10(9):3104-9.

29.

Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women.

Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ, McVeigh M, Lahti-Domenici J, Polyak K, Argani P, Naab T, Garrett E, Parmigiani G, Broome C, Sukumar S.

Clin Cancer Res. 2004 Mar 15;10(6):2052-7.

30.

Methylation profiling of benign and malignant breast lesions and its application to cytopathology.

Pu RT, Laitala LE, Alli PM, Fackler MJ, Sukumar S, Clark DP.

Mod Pathol. 2003 Nov;16(11):1095-101.

31.

DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.

Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, Sukumar S, Argani P.

Int J Cancer. 2003 Dec 20;107(6):970-5.

32.

Novel agents for chemoprevention, screening methods, and sampling issues.

Fackler MJ, Evron E, Khan SA, Sukumar S.

J Mammary Gland Biol Neoplasia. 2003 Jan;8(1):75-89. Review.

PMID:
14587864
33.

Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34- cell preparations.

Gao Z, Fackler MJ, Leung W, Lumkul R, Ramirez M, Theobald N, Malech HL, Civin CI.

Exp Hematol. 2001 Jul;29(7):910-21.

PMID:
11438214
34.

The adapter protein CrkL associates with CD34.

Felschow DM, McVeigh ML, Hoehn GT, Civin CI, Fackler MJ.

Blood. 2001 Jun 15;97(12):3768-75.

35.

Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity.

Jones RJ, Collector MI, Barber JP, Vala MS, Fackler MJ, May WS, Griffin CA, Hawkins AL, Zehnbauer BA, Hilton J, Colvin OM, Sharkis SJ.

Blood. 1996 Jul 15;88(2):487-91.

36.

CD34: structure, biology, and clinical utility.

Krause DS, Fackler MJ, Civin CI, May WS.

Blood. 1996 Jan 1;87(1):1-13. Review. No abstract available.

37.

Full-length but not truncated CD34 inhibits hematopoietic cell differentiation of M1 cells.

Fackler MJ, Krause DS, Smith OM, Civin CI, May WS.

Blood. 1995 Jun 1;85(11):3040-7.

38.

Characterization of murine CD34, a marker for hematopoietic progenitor and stem cells.

Krause DS, Ito T, Fackler MJ, Smith OM, Collector MI, Sharkis SJ, May WS.

Blood. 1994 Aug 1;84(3):691-701.

39.

Activated protein kinase C directly phosphorylates the CD34 antigen in acute lymphoblastic leukemia cells.

Sutherland DR, Fackler MJ, May WS, Matthews KE, Baker MA.

Leuk Lymphoma. 1992 Nov;8(4-5):337-44.

PMID:
1283964
40.
41.

Lymphohematopoiesis: role of growth factors in leukemogenesis and therapy.

Fackler MJ, Strauss LC.

Hematol Oncol Clin North Am. 1990 Aug;4(4):849-65. Review.

PMID:
2228899
42.

Activated protein kinase C directly phosphorylates the CD34 antigen on hematopoietic cells.

Fackler MJ, Civin CI, Sutherland DR, Baker MA, May WS.

J Biol Chem. 1990 Jul 5;265(19):11056-61.

43.

Positive stem cell selection--basic science.

Civin CI, Strauss LC, Fackler MJ, Trischmann TM, Wiley JM, Loken MR.

Prog Clin Biol Res. 1990;333:387-401; discussion 402.

PMID:
1689854
44.

Antigenic analysis of hematopoiesis. IV. The My-11 hematopoietic cell surface antigen is expressed by myelomonocytic and lymphoid, but not erythroid, progenitor cells.

Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH, Loken MR, Civin CI.

Exp Hematol. 1986 Nov;14(10):935-45.

PMID:
3464448
45.

Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells.

Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH.

J Immunol. 1984 Jul;133(1):157-65.

PMID:
6586833

Supplemental Content

Loading ...
Support Center